Date: November 07, 2025
Ref. No.: KDL/SE/073/2025-26

To,	To,
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Exchange Plaza, Plot No. C-1, Block G,
25th Floor, Phiroze Jeejeebhoy Towers	Bandra Kurla Complex, Bandra (East)
Dalal Street, Mumbai- 400001	Mumbai – 400051
Scrip Code: 543328	**NSE Symbol:** KRSNAA

Dear Sir/Madam,

Sub: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2025.

For **Krsnaa Diagnostics Limited**

Sujoy Sudipta Bose

Digitally signed by Sujoy Sudipta Bose
Date: 2025.11.07 20:01:51 +05'30'

Krsnaa Diagnostics Limited

Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Krsnaa Diagnostics Ltd.
S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)
020 27402400 | info@krsnaa.in
www.krsnaadiagnostics.com

krsnaa DIAGNOSTICS LET'S DO GOOD...

Highest-Ever PAT and Margin Momentum Highlights Business Strength; Rajasthan Rollout Unlocks Future Upside

Pune, November 07, 2025: Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA) is one of India's fastest-growing integrated diagnostic service providers. The Company today announced the results for the Half year & Quarter ending September 30, 2025.

Financial Performance Q2 FY2026

Revenue ₹ 2,060 mn 11% YoY

EBITDA ₹ 602 mn 18% YoY

PAT ₹ 239 mn 22% YoY

EPS ₹ 7.25 23% YoY

Financial Overview Q2 FY2026:

(Rs. Million)	Q2FY26	Q2FY25	Y-o-Y Growth	Q1FY26	Q-o-Q Growth	H1FY26	H1FY25	Y-o-Y Growth
Revenue from Operations	**2,060**	**1,863**	**11%**	**1,930**	**7%**	**3,990**	**3,566**	**12%**
Other Income	42	46		40		82	119	
Total Income	2,102	1,909		1,970		4,072	3,685	
EBITDA[1]	**602**	**509**	**18%**	**524**	**15%**	**1,126**	**951**	**18%**
Margin %	29%	27%		27%		28%	27%	
EBIT[1]	**398**	**318**	**25%**	**338**	**18%**	**736**	**603**	**22%**
Margin %	19%	17%		18%		18%	17%	
Profit After Tax	**239**	**196**	**22%**	**205**	**17%**	**445**	**375**	**19%**
Margin %	12%	11%		11%		11%	11%	
Reported `Diluted EPS	7.25	5.92	23%	6.25	16%	13.50	11.38	19%

Notes: 1. EBITDA excludes CSR and ESOP and EBIT includes Other Income

Commenting on the results, **Mr. Yash Mutha, Managing Director**, said:

"Krsnaa Diagnostics has delivered its highest-ever quarterly profit, reinforcing the strength and resilience of our business model. Revenue grew 12% year-on-year in H1 FY26, driven by expanding patient volumes and the growing confidence in our diagnostic network across India. EBITDA increased 18% year-on-year to ₹1,126 million, with margins improving to 28%, reflecting disciplined execution and strong operating leverage. Net profit rose 19% to ₹445 million, underscoring our focus on profitable and sustainable growth.

Over the years, we have built one of India's most efficient and inclusive diagnostic platforms, with a presence across Tier-II and Tier-III markets through our Public-Private Partnership model. This structure not only supports volume growth but also provides stability through long-term contracts and broad geographic diversification.

On the working capital side, our receivable cycle currently stands around 150+ days, reflecting a temporary transition linked to new central government payment norms under which states are aligning to RBI-linked disbursement mechanisms. Furthermore, Krsnaa has not recorded any bad debts since inception, underscoring the quality of our receivables and the credibility of our government partnerships.

Our focus remains on accelerating collections, optimizing cash flows, and reinvesting into high-impact growth initiatives such as the Rajasthan PPP — India's largest diagnostic project — which is progressing well and on schedule. With multiple labs going live in the coming months, we anticipate meaningful revenue contribution starting Q4 FY26 and a full-year impact in FY27.

With strong fundamentals, disciplined execution, and a clear growth roadmap, Krsnaa is well-positioned to deliver sustainable value and reinforce its leadership in India's diagnostics landscape."

Commenting on the Business, **Ms. Pallavi Bhatevara, Executive Director, said:**

"At Krsnaa Diagnostics, we remain steadfast in our commitment to quality, integrity, and patient-centric care. Leveraging our Public-Private Partnership (PPP) model, we provide free and high-quality diagnostic services across India, enabling millions to access essential healthcare. Our pan-India network and close collaboration with state governments have firmly established Krsnaa as a trusted and preferred partner in public healthcare delivery.

We are delighted to announce that for the first time in India, our company has received accreditation from the American College of Radiology (ACR) — a prestigious milestone marking the first-ever ACR recognition outside the United States. This global distinction stands as a testament to Krsnaa's unwavering pursuit of excellence and adherence to international standards in imaging and radiology. Additionally, we are also proud to continue holding the CAP (College of American Pathologists) accreditation, the only such recognition granted to a government diagnostic location in India.

These dual international accreditations underscore our relentless focus on quality, precision, and patient safety. They reaffirm Krsnaa's position as a benchmark for globally recognized diagnostic standards in India, strengthening our reputation among clinicians, government partners, and patients alike. Importantly, these achievements also contribute to higher patient trust, improved volumes, and stronger institutional credibility, supporting long-term growth.

Recently, we were honoured with the title of **"India's Most Trusted Integrated Diagnostic Brand"** at the Big FM – Big Impact Awards held in Vietnam, a testament to our unwavering commitment to quality, accessibility, and patient trust

With a foundation built on internationally accredited quality, a scalable nationwide platform, and a clear mission to make advanced diagnostics accessible to all, Krsnaa Diagnostics is well-positioned to capitalize on India's expanding healthcare landscape, drive sustainable growth, and enhance value for all stakeholders."

***

About Krsnaa Diagnostics:

Krsnaa Diagnostics Ltd. is India's fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 15 states and 3 Union Territories with 4,000+ centres across the country. Our mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and our commitment towards the same is what defines and differentiates us. We deliver clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for our patients in any corner of the country. With the most advanced technology in place, equipped with an advanced cloud based PACS workflow capable of rapid deployment and easy integration into flexible operational needs, accurate reports are delivered from well-qualified Radiologists and Pathologists from across the globe. We offer exceptional service with prompt turnaround of diagnostic reports, easy access to consultation with our team of diagnostic specialists, and the ability to handle diagnostic report needs. We provide world class healthcare diagnostics services at affordable rates with the approach of "Let's Do Good...".

For further information, please contact

Vivek Jain
Head - Investor Relation
Krsnaa Diagnostics Ltd.

+91 74107 00645
head.investor@krsnaa.in

Safe Harbour

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Krsnaa Diagnostics Ltd and its subsidiaries/ associates ("Krsnaa Diagnostics"). These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Krsnaa Diagnostics, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.